DK0830374T3 - Cytokin-, stress- og onkoproteinaktiverede humane proteinkinase-kinaser - Google Patents

Cytokin-, stress- og onkoproteinaktiverede humane proteinkinase-kinaser

Info

Publication number
DK0830374T3
DK0830374T3 DK96905233T DK96905233T DK0830374T3 DK 0830374 T3 DK0830374 T3 DK 0830374T3 DK 96905233 T DK96905233 T DK 96905233T DK 96905233 T DK96905233 T DK 96905233T DK 0830374 T3 DK0830374 T3 DK 0830374T3
Authority
DK
Denmark
Prior art keywords
stress
oncoprotein
cytokine
protein kinase
human protein
Prior art date
Application number
DK96905233T
Other languages
English (en)
Inventor
Roger J Davis
Shashi Gupta
Joel Raingeaud
Benoit Derijard
Original Assignee
Roger J Davis
Benoit Derijard
Shashi Gupta
Joel Raingeaud
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/446,083 external-priority patent/US5804427A/en
Application filed by Roger J Davis, Benoit Derijard, Shashi Gupta, Joel Raingeaud filed Critical Roger J Davis
Application granted granted Critical
Publication of DK0830374T3 publication Critical patent/DK0830374T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4736—Retinoblastoma protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
DK96905233T 1995-05-19 1996-01-26 Cytokin-, stress- og onkoproteinaktiverede humane proteinkinase-kinaser DK0830374T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/446,083 US5804427A (en) 1995-05-19 1995-05-19 Cytokine-, stress-, and oncoprotein-activated human protein kinase kinases
US08/530,950 US5736381A (en) 1995-05-19 1995-09-19 Cytokine-, stress-, and oncoprotein-activated human protein kinase kinases
PCT/US1996/001078 WO1996036642A1 (en) 1995-05-19 1996-01-26 Cytokine-, stress-, and oncoprotein-activated human protein kinase kinases

Publications (1)

Publication Number Publication Date
DK0830374T3 true DK0830374T3 (da) 2002-10-28

Family

ID=27034496

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96905233T DK0830374T3 (da) 1995-05-19 1996-01-26 Cytokin-, stress- og onkoproteinaktiverede humane proteinkinase-kinaser

Country Status (11)

Country Link
US (6) US5736381A (da)
EP (2) EP0830374B1 (da)
JP (1) JP3948571B2 (da)
AT (1) ATE220719T1 (da)
AU (1) AU710877B2 (da)
CA (1) CA2219487A1 (da)
DE (1) DE69622405T2 (da)
DK (1) DK0830374T3 (da)
ES (1) ES2179178T3 (da)
PT (1) PT830374E (da)
WO (1) WO1996036642A1 (da)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5736381A (en) 1995-05-19 1998-04-07 Davis; Roger J. Cytokine-, stress-, and oncoprotein-activated human protein kinase kinases
US6074862A (en) * 1995-12-20 2000-06-13 Signal Pharmaceuticals Inc. Mitogen-activated protein kinase kinase MEK6 and variants thereof
US7863429B2 (en) 1995-12-21 2011-01-04 Qlt Inc. Treatment of inflammatory diseases including psoriasis
US6013782A (en) * 1995-12-21 2000-01-11 Sunnybrook Health Sciences Center Integrin-linked kinase and its uses
US6001622A (en) 1995-12-21 1999-12-14 Sunnybrook Health Science Centre Integrin-linked kinase and its use
CA2239151C (en) * 1995-12-21 2011-03-29 Shoukat Dedhar Integrin-linked kinase, its inhibitors and methods of medical treatment using these inhibitors, gene therapy and pseudo-substrate inhibitors
US6699983B1 (en) 1995-12-21 2004-03-02 Sunnybrook Health Sciences Centre Integrin-linked kinase and its uses
WO1997044467A1 (en) * 1996-05-20 1997-11-27 Signal Pharmaceuticals, Inc. MITOGEN-ACTIVATED PROTEIN KINASE p38-2 AND METHODS OF USE THEREFOR
US5948885A (en) 1996-05-20 1999-09-07 Signal Pharmaceuticals, Inc. Mitogen-activated protein kinase p38-2 and methods of use therefor
US6677130B1 (en) 1996-05-20 2004-01-13 Signal Pharmaceuticals, Inc. Mitogen-activated protein kinase p38-2 and methods of use therefor
JP2001501481A (ja) * 1996-10-09 2001-02-06 メディカル、リサーチ、カウンシル Ｍａｐキナーゼ：ポリペプチド、ポリヌクレオチドおよびその使用
AU5610398A (en) * 1997-02-28 1998-09-18 Warner-Lambert Company Method of treating or preventing septic shock by administering a mek inhibitor
US5885803A (en) 1997-06-19 1999-03-23 Incyte Pharmaceuticals, Inc. Disease associated protein kinases
GB9717416D0 (en) * 1997-08-19 1997-10-22 Medical Res Council Polypeptides,polynucleotides and uses thereof
US6943000B2 (en) * 1997-10-03 2005-09-13 University Of Massachusetts JNK3 modulators and methods of use
US6492112B1 (en) 1997-12-31 2002-12-10 Chiron Corporation Mitogen-activated protein kinase kinase 7 (MKK7)
AU3354499A (en) * 1998-03-16 1999-10-11 Cadus Pharmaceutical Corporation Human mekk proteins, corresponding nucleic acid molecules, and uses therefor
US6897019B1 (en) 1998-04-17 2005-05-24 Tufts College Methods for treating and preventing insulin resistance and related disorders
US6207458B1 (en) 1998-05-07 2001-03-27 University Of Washigton/Stowers Insitute For Medical Research Proteins capable of regulating NF-κB JNK and apoptosis pathways and methods of using the same
JP2002514401A (ja) * 1998-05-13 2002-05-21 インサイト・ファーマスーティカルズ・インコーポレイテッド 細胞シグナルタンパク質
US6096543A (en) * 1998-11-20 2000-08-01 Isis Pharmaceuticals Inc. Antisense inhibition of human mek1 expression
US6033910A (en) * 1999-07-19 2000-03-07 Isis Pharmaceuticals Inc. Antisense inhibition of MAP kinase kinase 6 expression
US6010906A (en) * 1999-07-21 2000-01-04 Isis Pharmaceuticals Inc. Antisense modulation of Jun N-terminal kinase kinase-1 expression
US6376747B1 (en) * 1999-08-27 2002-04-23 Her Majesty The Queen In Right Of Canada As Represented By The Minister Of Agriculture And Agri-Food Canada Plant-derived map kinase kinase
AU1630501A (en) * 1999-10-08 2001-04-23 Superarray, Inc. Compositions and methods for detecting protein modification and enzymatic activity
EP1278859A2 (en) * 2000-04-10 2003-01-29 Sugen, Inc. Human protein kinases and protein kinase-like enzymes
EP1289523A1 (en) * 2000-06-01 2003-03-12 Merck & Co., Inc. Use of (di-substituted-phenyl)-pyrimidinyl-imidazole derivatives as jnk-inhibitors
US6824989B1 (en) * 2000-09-01 2004-11-30 Upstate Biotechnology, Inc. Recombinant monoclonal antibody to phosphotyrosine-containing proteins
US6498035B1 (en) * 2000-09-08 2002-12-24 Isis Pharmaceuticals, Inc. Antisense modulation of MEKK3 expression
EP1345603A4 (en) 2000-12-20 2004-09-08 Merck & Co Inc P38 KINASE INHIBITORS (HALO-BENZO CARBONYL) HETEROCYCLO- FUSIONNES PHENYL
DE60228419D1 (de) * 2001-02-15 2008-10-02 Sinai School Medicine Hemmung der atf2-aktivität zur behandlung von krebs
WO2002069977A1 (en) 2001-03-01 2002-09-12 Hollis-Eden Pharmaceuticals, Inc. Use of certain steroids for treatment of blood cell deficiencies
WO2003023362A2 (en) * 2001-09-12 2003-03-20 The Regents Of The University Of California Methods of ameliorating arthritis by modulating jnk signalsome activity
GB0224013D0 (en) * 2002-10-15 2002-11-27 Oxford Glycosciences Uk Ltd A protein involved in therapy
WO2005109001A2 (en) * 2004-05-12 2005-11-17 Galapagos N.V. Methods, compositions and compound assays for inhibiting amyloid-beta protein production
WO2006029470A1 (en) * 2004-09-17 2006-03-23 Walsh, Barbara Casual personnel recruitment method and system
US7994298B2 (en) * 2004-09-24 2011-08-09 Trustees Of Dartmouth College Chimeric NK receptor and methods for treating cancer
CA2693694A1 (en) * 2007-06-08 2008-12-11 University Of Massachusetts Mixed lineage kinases and metabolic disorders
WO2010151638A1 (en) 2009-06-25 2010-12-29 Medical College Of Georgia Research Institute, Inc. Jnk inhibitors for use in treating spinal muscular atrophy
US10190096B2 (en) 2014-12-18 2019-01-29 President And Fellows Of Harvard College Methods for generating stem cell-derived β cells and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995028421A1 (en) * 1993-04-15 1995-10-26 National Jewish Center For Immunology And Respiratory Medicine Method and product for regulating cell responsiveness to external signals
US5405941A (en) * 1993-04-15 1995-04-11 National Jewish Center For Immunology And Respiratory Medicine MEKK protein, capable of phosphorylating MEK
US5981265A (en) * 1993-04-15 1999-11-09 National Jewish Center For Immunology And Respiratory Medicine Methods for regulating MEKK protein activity
SE503628C2 (sv) * 1994-07-05 1996-07-22 Vikthygien Ab Mätdon
US5736381A (en) 1995-05-19 1998-04-07 Davis; Roger J. Cytokine-, stress-, and oncoprotein-activated human protein kinase kinases

Also Published As

Publication number Publication date
ATE220719T1 (de) 2002-08-15
EP0830374A1 (en) 1998-03-25
US20020102691A1 (en) 2002-08-01
US20090053231A1 (en) 2009-02-26
JP2002503946A (ja) 2002-02-05
US6541605B1 (en) 2003-04-01
JP3948571B2 (ja) 2007-07-25
US5736381A (en) 1998-04-07
DE69622405D1 (de) 2002-08-22
WO1996036642A1 (en) 1996-11-21
AU4904696A (en) 1996-11-29
ES2179178T3 (es) 2003-01-16
US6174676B1 (en) 2001-01-16
PT830374E (pt) 2002-11-29
AU710877B2 (en) 1999-09-30
EP0830374A4 (en) 1998-10-07
DE69622405T2 (de) 2003-03-27
EP0830374B1 (en) 2002-07-17
CA2219487A1 (en) 1996-11-21
EP1251177A3 (en) 2003-04-23
US20050272077A1 (en) 2005-12-08
EP1251177A2 (en) 2002-10-23

Similar Documents

Publication Publication Date Title
DK0830374T3 (da) Cytokin-, stress- og onkoproteinaktiverede humane proteinkinase-kinaser
DE68929475D1 (de) Wässrige Copolymer-Dispersion zur Lederbehandlung
NO880185D0 (no) Individuelt justerbart putesystem.
DE68908142D1 (de) Vorrichtung zur steuerung eines elektromagnetisch angetriebenen ventils.
DE69114115D1 (de) Vorrichtung zum Ausführen von Kopf- und Fuss-Trendelenburgtherapie.
DE3850140D1 (de) Biokompatibles Kammerunterstützungs- und Arrythmik-Steuergerät.
DE69629968D1 (de) Vorrichtung zur Stimulation der Herzfunktion
DE3856270D1 (de) Vorrichtung zur Musiktonsteuerung
DE3788773D1 (de) Vorrichtung zur Feinverstellung und Vorrichtung zum Steuern dieser Verstellungen.
DE69429797D1 (de) Vorrichtung zur Stimulation des Herzens
DE69310834T2 (de) Vorrichtung für die Neigungsverstellung von Bett- oder Sofateilen
DE69833946D1 (de) Durch cytokine, stress und oncoproteine aktivierte kinasen von menschlicher proteinkinase
DE68915010D1 (de) Schreibkopfsteuergerät.
DE69712502T2 (de) Vorrichtung zur stimulation der herzfunktion
DE69106793D1 (de) Vorrichtung zur Aufhängungsregelung.
DE423591T1 (de) Vorrichtung zum kontrollierten und unabhaengigen verschwenken von richt- und biegeplattformen.
DK88989D0 (da) Substituerede pyrimidiner, fremgangsmaade og mellemprodukter til deres fremstilling samt deres anvendelse
DE68922259D1 (de) Vorrichtung zur Durchflusssteuerung.
DK494589D0 (da) Substituerede 1,3,5-triazintrioner og deres anvendelse samt mellemprodukter til deres fremstilling
DE69430155D1 (de) Vorrichtung zur Stimulation des Herzens
DE58902927D1 (de) Vorrichtung zur daempfung von luft- und koerperschallschwingungen.
DE68911784D1 (de) Druckabhängige und elektrisch gesteuerte Durchflussmengenregelvorrichtung.
DE69108116T2 (de) Vorrichtung zur Stimulation lebenden Gewebes.
DK378488A (da) Anellerede iminoazoler og iminoaziner, fremgangsmaade til fremstilling heraf og deres anvendelse med herbicid virkning
DE58908586D1 (de) Tauchtiefengesteuerte Ausblasventil-Einrichtung.